In December 2025, Genentech, part of the Roche Group, received U.S. FDA accelerated approval for Lunsumio VELO, a subcutaneous formulation of mosunetuzumab for adults with relapsed or refractory follicular lymphoma after at least two prior systemic therapies, cutting administration time from hours to about one minute.
This approval underscores Roche’s push toward more patient‑centric oncology treatments that ease clinic resource constraints while expanding options in later-line blood cancer care.
We’ll now examine how this faster, subcutaneous Lunsumio VELO offering may influence Roche’s investment narrative built around high-value biologics and innovation.
Trump has pledged to “unleash” American oil and gas and these 22 US stocks have developments that are poised to benefit.
To own Roche, I think you need to believe in its ability to keep refreshing a high‑value oncology and diagnostics portfolio while managing pricing and patent pressures. The Lunsumio VELO approval strengthens the near term oncology innovation story, but does not materially change the biggest current risk, which remains pricing and policy pressure across major markets that could weigh on group revenue and margins.
Among recent announcements, the cobas 6800/8800 systems 2.0 upgrade looks particularly relevant, because it reinforces the diagnostics catalyst built around higher‑throughput, more automated testing platforms that can deepen recurring revenue streams. Together with patient‑centric launches like Lunsumio VELO, it supports the idea that Roche’s most important upside drivers lie in combining differentiated medicines with diagnostics that make care more efficient for hospitals and labs.
Yet behind this innovation story, intensifying global healthcare cost pressure could still limit Roche’s pricing power, which is something investors should be aware of…
Read the full narrative on Roche Holding (it’s free!)
Roche Holding’s narrative projects CHF67.3 billion revenue and CHF16.8 billion earnings by 2028. This requires 1.9% yearly revenue growth and an earnings increase of about CHF7.4 billion from CHF9.4 billion today.
Uncover how Roche Holding’s forecasts yield a CHF323.28 fair value, in line with its current price.
SWX:ROG 1-Year Stock Price Chart
Nine fair value estimates from the Simply Wall St Community span roughly CHF295 to CHF742 per share, showing how far apart individual views can be. When you set that against the risk of tighter global healthcare pricing, it underlines why many investors look at several perspectives before forming a view on Roche’s long term earnings power.
Explore 9 other fair value estimates on Roche Holding – why the stock might be worth over 2x more than the current price!
Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ROG.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com